Skip to main content
Premium Trial:

Request an Annual Quote

Sphere Fluidics Closes $4.8M Financing Round

NEW YORK (GenomeWeb) – Sphere Fluidics announced today that it has closed an additional tranche of $2.9 million in a funding round, securing a total of$4.8 million.

According to Sphere, it will use the funding for working capital for the Cyto-Mine single-cell analysis system, expansion of the UK facility, and to open a new US sales office and demo lab in California, thereby doubling the company's workforce. The Cyto-Mine system automates single-cell screening, sorting, imaging, and dispensing to speed biopharmaceutical discovery.

The funding round was led by Greenwood Way Capital, who invested a total of $4.3 million, as well as 24Haymarket Limited, and other individual investors.

Sphere Fluidics previously closed a $2 million investment round in January.

"Due to our oversubscribed investment round earlier this year, we decided to add on a second tranche to accommodate this additional interest," Sphere Fluidics CEO Frank Craig said in a statement. "We are currently recruiting and looking at prospective new facilities in the UK and California to support the growth of our commercial and scientific activities."

The Scan

Time to Act

A new report urges the UK to consider regulations to protect against the misuse of genomic technologies, according to the Guardian.

Fulgent Seeking Defamation Suit

Fulgent Genetics says it plans to sue Los Angeles County Sheriff Alex Villanueva for defamation, the Los Angeles Times reports.

Speeding Gene-Edited Crops

Reuters reports that China's new trial rules will make it easier to grow gene-edited crops there.

Nucleic Acids Research Papers on Viral Recombination, Pan-Cancer Mutations, SARS-CoV-2 Variability

In Nucleic Acids Research this week: updated pipeline to detect viral recombination, mutational patterns in tumor samples, and more.